> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Priority Review Voucher Used on Mayzent NDA
- URL: https://www.fdaweb.com/fda-priority-review-voucher-used-on-mayzent-nda/
- Published: 2019-06-03T12:00:00.000Z
- Updated: 2026-09-15T01:30:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144240

*Federal Register* notice: FDA has permitted the redemption of a priority review voucher associated with the recent approval of a Novartis NDA for Mayzent (siponimod) tablets, indicated for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-11522.pdf?ref=fdaweb.com).